139 related articles for article (PubMed ID: 9474149)
21. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Anticancer Res; 2009 Oct; 29(10):4201-4. PubMed ID: 19846973
[TBL] [Abstract][Full Text] [Related]
22. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
23. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
24. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
25. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
26. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
[TBL] [Abstract][Full Text] [Related]
27. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
28. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
29. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
[TBL] [Abstract][Full Text] [Related]
31. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
32. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
35. Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder.
Sato M; Yanai H; Morito T; Oda W; Shin-no Y; Yamadori I; Tshushima T; Yoshino T
Pathol Int; 2011 Aug; 61(8):456-60. PubMed ID: 21790859
[TBL] [Abstract][Full Text] [Related]
36. A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.
Oh JJ; Ji SH; Choi DK; Gong IH; Kim TH; Park DS
Oncology; 2010; 79(5-6):440-6. PubMed ID: 21487231
[TBL] [Abstract][Full Text] [Related]
37. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
[TBL] [Abstract][Full Text] [Related]
38. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
39. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]